Education
About Us
Working with TipRanks
Follow Us
4DMedical Ltd (AU:4DX)
ASX:4DX
4DX Stock Chart & Stats
AU$3.97
<AU$0.01(1.02%)
At close: 4:00 PM EST
AU$3.97
<AU$0.01(1.02%)
Day’s Range― - ―
52-Week RangeAU$0.23 - AU$5.42
Previous CloseN/A
Volume497.15K
Average Volume (3M)10.77M
Market Cap
AU$2.14B
Enterprise ValueAU$2.26B
Total Cash (Recent Filing)AU$6.88M
Total Debt (Recent Filing)AU$4.31M
Price to Earnings (P/E)―
Beta2.11
Next Earnings
Mar 04, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding570,191,200
10 Day Avg. Volume5,850,211
30 Day Avg. Volume10,774,582
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.80
Price to Sales (P/S)8.81
P/FCF Ratio-1.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.85Price Target Upside-3.02% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring And Diversified Revenue ModelA mix of recurring software licences, per-scan fees and services creates multiple monetization levers and customer stickiness. Over 2-6 months this supports predictable revenue tail from renewals while per-use growth scales with clinical adoption and imaging volumes.
Proprietary XV Imaging PlatformOwning a specialized platform that delivers quantitative ventilation and perfusion assessments creates a durable competitive position. Clinical utility and technical specialization raise switching costs for hospitals and support long-term adoption in diagnostics, trials and care pathways.
Conservative Financial LeverageRelatively low leverage and a stable equity ratio provide financial flexibility to support ongoing R&D and commercialization. This conservatism reduces bankruptcy risk and gives time to execute product rollouts without immediate refinancing pressure over the medium term.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flows mean the business consumes cash to operate and grow. That reliance on external funding or equity raises dilution and execution risk, constraining investment in sales, regulatory work, and commercialization in the coming months.
Declining Revenue And Weak MarginsA reported decline in revenue alongside negative EBIT and net margins signals weak commercial traction or pricing pressure. Without near-term topline recovery, the company will struggle to achieve margin sustainability and fund expansion from operating profits.
Negative Return On EquityNegative ROE indicates the company is destroying shareholder capital rather than generating returns. If losses persist, investor willingness to provide growth capital may wane, limiting runway for clinical validation and broader hospital rollouts over the medium term.
4DMedical Ltd News
4DX FAQ
What was 4DMedical Ltd’s price range in the past 12 months?
4DMedical Ltd lowest share price was AU$0.23 and its highest was AU$5.42 in the past 12 months.
What is 4DMedical Ltd’s market cap?
4DMedical Ltd’s market cap is AU$2.14B.
When is 4DMedical Ltd’s upcoming earnings report date?
4DMedical Ltd’s upcoming earnings report date is Mar 04, 2026 which is in 13 days.
How were 4DMedical Ltd’s earnings last quarter?
4DMedical Ltd released its earnings results on Aug 28, 2025. The company reported -AU$0.109 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.109.
Is 4DMedical Ltd overvalued?
According to Wall Street analysts 4DMedical Ltd’s price is currently Overvalued.
Does 4DMedical Ltd pay dividends?
4DMedical Ltd does not currently pay dividends.
What is 4DMedical Ltd’s EPS estimate?
4DMedical Ltd’s EPS estimate is -0.04.
How many shares outstanding does 4DMedical Ltd have?
4DMedical Ltd has 570,191,200 shares outstanding.
What happened to 4DMedical Ltd’s price movement after its last earnings report?
4DMedical Ltd reported an EPS of -AU$0.109 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 18.75%.
Which hedge fund is a major shareholder of 4DMedical Ltd?
Currently, no hedge funds are holding shares in AU:4DX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
4DMedical Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
AU$3.85 (-3.02% Downside)
AU$3.85 (-3.02% Downside)
Blogger Sentiment
Bullish
AU:4DX Sentiment 89%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth AU$9.6M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
205.21%
12-Months-Change
Fundamentals
Return on Equity
-44.49%
Trailing 12-Months
Asset Growth
-21.00%
Trailing 12-Months
Company Description
4DMedical Ltd
4DMedical Limited operates as a medical technology company in Australia and the United States. It commercializes XV Technology, a four-dimensional lung imaging technology. The company also offers software as a service delivery model; XV lung ventilation analysis software; Permetium, a preclinical imaging system which quantify regional changes in pulmonary function; and AccuVent 200, a small animal ventilator. The company was incorporated in 2012 and is based in Carlton, Australia.
4DX Stock 12 Month Forecast
Average Price Target
AU$3.85
▼(-3.02% Downside)
Technical Analysis
Impedimed Limited
―
Cyclopharm Limited
―
Micro-X Ltd.
―
Aroa Biosurgery Ltd
―
EMvision Medical Devices Ltd.
―
Options Prices
Currently, No data available
---